Prognostic Utility of Total (68)Ga-DOTATATE-Avid Tumor Volume in Patients with Neuroendocrine Tumors

BACKGROUND & AIMS: Survival times vary among patients with neuroendocrine tumors (NETs)—even among those with the same site, stage, and grade of primary tumor. This makes it difficult to select treatment for patients with unresectable NETs, because some patients can survive decades without treat...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Gastroenterology
Autors principals: Tirosh, Amit, Papadakis, Georgios Z., Millo, Corina, Hammoud, Dima, Sadowski, Samira M., Herscovitch, Peter, Pacak, Karel, Marx, Stephen J., Yang, Lily, Nockel, Pavel, Shell, Jasmine, Green, Patience, Keutgen, Xavier M., Patel, Dhaval, Nilubol, Naris, Kebebew, Electron
Format: Artigo
Idioma:Inglês
Publicat: 2017
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5847442/
https://ncbi.nlm.nih.gov/pubmed/29155309
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1053/j.gastro.2017.11.008
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars